Marketplace

Pharmacy Policy Updates December 2025

The following policies are effective January 1, 2026





AT CARESOURCE, WE LISTEN TO OUR PROVIDERS, AND WE STREAMLINE OUR BUSINESS PRACTICES TO MAKE IT EASIER FOR YOU TO WORK WITH US.

We have worked to create a predictable cycle for releasing administrative, pharmacy, and reimbursement policies, so you know what to expect.

Check back each month for a consolidated network notification of policy updates from CareSource.

HOW TO USE THIS NETWORK NOTIFICATION

- Reference the list of policy updates.
- Note the effective date and impacted plans for each policy.
- Click the hyperlinked policy title to open the webpage containing the policy location.

FIND OUR POLICIES ONLINE

To access all CareSource policies, visit **CareSource.com** > Providers > Tools & Resources > <u>Provider Policies</u>. Select your plan and state, then Pharmacy, Reimbursement, or Administrative. Each policy page has an archive where you can find previous versions of policies.



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
ADALIMUMAB (HUMIRA, ABRILADA, AMJEVITA, CYLTEZO, HADLIMA, HULIO, HYRIMOZ, IDACIO, YUFLYMA, YUSIMRY)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
AJOVY (FREMANEZUMAB- VFRM)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
ANDEMBRY (GARADACIMAB-GXII)	01/01/2026	ALL MARKETPLACE PLANS	NEW POLICY
AUBAGIO (TERIFLUNOMIDE)	01/01/2026	ALL MARKETPLACE PLANS	ANNUAL REVIEW; NO UPDATES
BAFIERTAM (MONOMETHYL FUMARATE)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
BERINERT (C1 ESTERASE INHIBITOR (HUMAN))	01/01/2026	ALL MARKETPLACE PLANS	ANNUAL REVIEW; NO UPDATES
CIMZIA (CERTOLIZUMAB PEGOL)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
CINRYZE (C1 ESTERASE INHIBITOR (HUMAN))	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
DAYBUE (TROFINETIDE)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
DOPTELET (AVATROMBOPAG)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
DUPIXENT (DUPILUMAB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
EGRIFTA SV, EGRIFTA WR (TESAMORELIN)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
EKTERLY (SEBETRALSTAT)	01/01/2026	ALL MARKETPLACE PLANS	NEW POLICY
EMPAVELI (PEGCETACOPLAN)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
ENTYVIO (VEDOLIZUMAB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
FINGOLIMOD (GILENYA, TASCENSO ODT)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
FIRAZYR OR SAJAZIR (ICATIBANT)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
GAMIFANT (EMAPALUMAB-LZSG)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
GENDER IDENTITY HORMONE THERAPY	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
HAEGARDA (C1 ESTERASE INHIBITOR (HUMAN))	01/01/2026	ALL MARKETPLACE PLANS	ANNUAL REVIEW; NO UPDATES
HEMOPHILIA AND OTHER CLOTTING DISORDERS	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
IMMUNE GLOBULIN (IVIG AND SCIG)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
INFLIXIMAB (AVSOLA, INFLECTRA, REMICADE, RENFLEXIS, ZYMFENTRA)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
INGREZZA (VALBENAZINE)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
INHALED PROSTACYCLINS FOR PULMONARY ARTERIAL HYPERTENSION: TYVASO, YUTREPIA (TREPROSTINIL) AND VENTAVIS (ILOPROST)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
KALBITOR (ECALLANTIDE)	01/01/2026	ALL MARKETPLACE PLANS	ANNUAL REVIEW; NO UPDATES
KISUNLA (DONANEMAB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
KUVAN (SAPROPTERIN)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
LEMTRADA (ALEMTUZUMAB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
LEQSELVI (DEURUXOLITINIB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
LITFULO (RITLECITINIB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
MAVENCLAD (CLADRIBINE)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
MAVYRET (GLECAPREVIR AND PIBRENTASVIR)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
MAYZENT (SIPONIMOD)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
MULPLETA (LUSUTROMBOPAG)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
NITISINONE (ORFADIN, NITYR, HARLIKU)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
NOVANTRONE (MITOXANTRONE)	01/01/2026	ALL MARKETPLACE PLANS	ANNUAL REVIEW; NO UPDATES
NPLATE (ROMIPLOSTIM)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
NUCALA (MEPOLIZUMAB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
OLUMIANT (BARICITINIB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
OMVOH (MIRIKIZUMAB- MRKZ)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
ORLADEYO (BEROTRALSTAT)	01/01/2026	ALL MARKETPLACE PLANS	ANNUAL REVIEW; NO UPDATES
OTEZLA, OTEZLA XR (APREMILAST)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
OXLUMO (LUMASIRAN)	01/01/2026	ALL MARKETPLACE PLANS	ANNUAL REVIEW; NO UPDATES
PALYNZIQ (PEGVALIASE- PQPZ)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
PONVORY (PONESIMOD)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
PROLIA (DENOSUMAB) AND BIOSIMILARS (JUBBONTI, STOBOCLO)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
PROMACTA AND ALVAIZ (ELTROMBOPAG)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
QALSODY (TOFERSEN)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
RADICAVA (EDARAVONE INJECTION); RADICAVA ORS (EDARAVONE ORAL SUSPENSION)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
RIVFLOZA (NEDOSIRAN)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
RUCONEST (C1 ESTERASE INHIBITOR (RECOMBINANT))	01/01/2026	ALL MARKETPLACE PLANS	ANNUAL REVIEW; NO UPDATES



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
SEPHIENCE (SEPIAPTERIN)	01/01/2026	ALL MARKETPLACE PLANS	NEW POLICY
SHORT-ACTING SOMATROPIN INJECTIONS FOR GROWTH HORMONE DEFICIENCY (GENOTROPIN, HUMATROPE, NORDITROPIN, NUTROPIN, OMNITROPE, SAIZEN, ZOMACTON)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
SIMPONI (GOLIMUMAB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
SKYCLARYS (OMAVELOXOLONE)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
SKYRIZI (RISANKIZUMAB- RZAA)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
SKYTROFA (LONAPEGSOMATROPIN)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
SOGROYA (SOMAPACITAN-BECO)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
STELARA (USTEKINUMAB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
SYLVANT (SILTUXIMAB)	01/01/2026	ALL MARKETPLACE PLANS	NEW POLICY
TAKHZYRO (LANADELUMAB-FLYO)	01/01/2026	ALL MARKETPLACE PLANS	ANNUAL REVIEW; NO UPDATES
TAVALISSE (FOSTAMATINIB DISODIUM HEXAHYDRATE)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
TECFIDERA (DIMETHYL FUMARATE)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
TREMFYA (GUSELKUMAB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
VELSIPITY (ETRASIMOD)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
VUMERITY (DIROXIMEL FUMARATE)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
XELJANZ/XELJANZ XR (TOFACITINIB)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
XGEVA (DENOSUMAB) AND BIOSIMILARS (WYOST, OSENVELT)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
YEZTUGO (LENACAPAVIR)	01/01/2026	ALL MARKETPLACE PLANS	NEW POLICY
YUTIQ (FLUOCINOLONE ACETONIDE)	01/01/2026	ALL MARKETPLACE PLANS	ARCHIVED POLICY
ZEPOSIA (OZANIMOD)	01/01/2026	ALL MARKETPLACE PLANS	REVISED POLICY
ABECMA (IDECABTAGENE VICLEUCEL)	01/01/2026	ALL MARKETPLACE PLANS	ARCHIVED POLICY (PLEASE REFER TO ONCOLOGY REGIMENS POLICY)
AUCATZYL (OBECABTAGENE AUTOLEUCEL)	01/01/2026	ALL MARKETPLACE PLANS	ARCHIVED POLICY (PLEASE REFER TO ONCOLOGY REGIMENS POLICY)
BREYANZI (LISOCABTAGENE MARALEUCEL)	01/01/2026	ALL MARKETPLACE PLANS	ARCHIVED POLICY (PLEASE REFER TO ONCOLOGY REGIMENS POLICY)
CARVYKTI (CILTACABTAGENE AUTOLEUCEL)	01/01/2026	ALL MARKETPLACE PLANS	ARCHIVED POLICY (PLEASE REFER TO ONCOLOGY REGIMENS POLICY)



POLICY NAME	EFFECTIVE DATE	PLAN	IMPACT
KYMRIAH (TISAGENLECLEUCEL)	01/01/2026	ALL MARKETPLACE PLANS	ARCHIVED POLICY (PLEASE REFER TO ONCOLOGY REGIMENS POLICY)
TECARTUS (BREXUCABTAGENE AUTOLEUCEL)	01/01/2026	ALL MARKETPLACE PLANS	ARCHIVED POLICY (PLEASE REFER TO ONCOLOGY REGIMENS POLICY)
YESCARTA (AXICABTAGENE CILOLEUCEL)	01/01/2026	ALL MARKETPLACE PLANS	ARCHIVED POLICY (PLEASE REFER TO ONCOLOGY REGIMENS POLICY)